AVN-211

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
AVN-211
AVN-211.svg
Identifiers
ChemSpider
  • 26387125
ChEMBL
  • CHEMBL1668500
Chemical and physical data
Formula C15H15N3O2S2
Molar mass 333.42 g·mol−1
3D model (JSmol)
  • Interactive image

AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia.[1][2][3] In early 2011, it successfully completed phase IIa clinical trials,[1][4] with benefits on positive symptoms and some procognitive effects observed,[5] and in mid 2013, phase IIb clinical trials for schizophrenia began.[6] Avineuro Pharmaceuticals has also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease in 2015.[6][7]

See also

References

  1. ^ a b Sylvain Celanire; Sonia Poli (13 October 2014). Small Molecule Therapeutics for Schizophrenia. Springer. pp. 31, 37. ISBN 978-3-319-11502-3. 
  2. ^ Pharmacology of 5-HT6 receptors. Academic Press. 7 December 2010. pp. 164–. ISBN 978-0-12-384977-9. 
  3. ^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. 
  4. ^ http://www.avineuro.com/avineuro-pharmaceuticals-inc-reports-positive-phase-2a-clinical-proof-of-concept-trial-results-on-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/
  5. ^ Morozova, Margarita A.; Lepilkina, Taisiya A.; Rupchev, Georgy E.; Beniashvily, Allan G.; Burminskiy, Denis S.; Potanin, Sergey S.; Bondarenko, Evgeny V.; Kazey, Vasily I.; Lavrovsky, Yan; Ivachtchenko, Alexandre V. (2013). "Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study". CNS Spectrums. 19 (04): 316–323. doi:10.1017/S1092852913000394. ISSN 1092-8529. 
  6. ^ a b http://www.avineuro.com/avineuro-pharmaceuticals-inc-announces-beginning-of-phase-2b-clinical-studies-of-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/
  7. ^ Ivachtchenko AV, Lavrovsky Y, Ivanenkov YA (2016): "AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer’s Disease", Molecular Pharmaceutics, 13 (3), 945–963. PMID 26886442

External links

  • Pipeline - Avineuro Pharmaceuticals, Inc.


Retrieved from "https://en.wikipedia.org/w/index.php?title=AVN-211&oldid=815848506"
This content was retrieved from Wikipedia : http://en.wikipedia.org/wiki/AVN-211
This page is based on the copyrighted Wikipedia article "AVN-211"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA